Sudan Ebola Pseudovirus

Comprehensive Neutralization Assay Solutions for Advancing Sudan ebolavirus Research

Get your pseudovirus

Sudan Ebola Pseudovirus

This Ebola pseudovirus is pseudotyped with the Glycoprotein of the Sudan variant (GenBank: WEY06140.1). These pseudoviruses carry a modified genome that expresses a luciferase (or GFP) reporter gene.

QC report example

Sudan Ebola Pseudovirus Advantages

Lot to lot functionally validated

Infectivity and neutralization are evaluated for each batch

Up to 1,000 reactions per mL (96-well plate)

Get a signal-to-background ratio of ≥10³ with 1 µL per well

Characterization of thermal stability

Stable at least 10 month at -80 °C

Support high-throughput screening

QC report get a quote

Sudan Ebola Pseudovirus Features

Infectious titer of at least 10⁵ RLU/µL

The transduction efficiency is evaluated using HEK293T cells

Enable specific detection

Expression of Sudan Ebo-GP on the surface of the pseudovirus

Enhanced safety

Our pseudoviruses use a 3rd-generation lentivirus core and must be handled in BSL-2 conditions.

Lead Time: 1 - 3 week

We provide you with freshly produced pseudoviruses

Get a quote

Sudan Ebola Pseudovirus Applications

Pseudoviruses provide a safe and versatile platform for Sudan ebolavirus research and the development of therapeutic countermeasures. These pseudoviruses have several important applications in research and development, including:

Vaccine Development

They are used to test the efficacy of new vaccines by evaluating their ability to induce neutralizing immune responses without the need for live pathogenic viruses.

Neutralizing Monoclonal Antibody Screening

Pseudoviruses enable rapid and safe screening of monoclonal antibodies targeting Sudan ebolavirus

Antiviral Resistance Studies

They help study viral mutations and evaluate how these mutations affect sensitivity to antiviral treatments.

Fundamental Research on Viral Entry

Pseudoviruses are used to understand the mechanisms of viral entry into host cells, which is crucial for developing new therapies targeting these processes.

Treatment Efficacy Testing

They allow for the quick assessment of new antiviral agents’ effectiveness in controlled environments without the risks associated with highly pathogenic viruses.

get a quote

Sudan Ebolavirus Background

The Sudan ebolavirus (Orthoebolavirus sudanense) is one of the pathogenic species in the Orthoebolavirus genus of the Filoviridae family and is a cause of severe viral hemorrhagic fever known as Sudan virus disease (SVD). It was first identified in 1976 during an outbreak in what is now South Sudan and has since caused multiple outbreaks, predominantly in Uganda and Sudan. SVD presents with sudden onset of fever, fatigue, muscle pain, vomiting, diarrhea, and in some cases unexplained bleeding, and has historically exhibited high case fatality rates often around 40–60% or higher depending on the outbreak. The virus is zoonotic, with transmission to humans thought to occur through contact with infected wildlife reservoirs such as fruit bats, and human-to-human spread occurs through direct contact with infectious bodily fluids. Unlike the Zaire ebolavirus strain, for which licensed vaccines exist, there is currently no approved vaccine or specific antiviral treatment for Sudan ebolavirus, though several vaccine candidates and clinical trials are under development (CDC, WHO).

Sudan Ebola Pseudovirus in Publications

June 21, 2021

The Application of a Safe Neutralization Assay for Ebola Virus Using Lentivirus-Based Pseudotyped Virus

Read more >

×

Get your document

Fill out the form below to get your document

"*" indicates required fields

Name*

First Last

Email*

This field is hidden when viewing the form

Document URL

Documentations

Sudan Ebola - CoA

See all CoAs

MSDS

Access MSDS

×

Get your document

Fill out the form below to get your document

"*" indicates required fields

Name*

First Last

Email*

This field is hidden when viewing the form

Document URL